Generated by AI
Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.
Website4600 South Syracuse Street
Denver, CO, 80237
United States
The latest articles about PALI.
Palisade Bio's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. I rate PALI stock as Buy.
Summary of Oct 28's posts. Generated by AI.
Summary of Dec 29's posts. Generated by AI.
Summary of Apr 5's posts. Generated by AI.
Investors talking about PALI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.